Clinical trials: Depressed
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.
- Trial name
- NCT00672958
- Testing
- Vortioxetine
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Depressive Disorder, Major
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
The main purpose of this study is to evaluate the efficacy of saredutant 100mg or 30mg once daily in combination with paroxetine 20mg once daily compared to saredutant placebo in combination with paroxetine 20mg once daily in…
- Trial name
- COMPASS (NCT00629551)
- Testing
- saredutant (SR48968), paroxetine
- Where
- 8 sites in United States, Chile and 6 more
- Volunteers
- 825 people
- Sponsor
- Sanofi
Healthy Volunteer
A Screening Study To Assess The Cognition Status in Healthy Volunteers
This multi-center screening study will conduct a cognition assessment to collect reference data for comparison to patients with depression in healthy volunteers. Data will be collected for 6 weeks.
- Trial name
- NCT01926873
- Where
- 12 sites in United States, Germany and 1 more
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Postpartum Depression
A Study of BRII-297 in Healthy Adult Subjects
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of BRII-297 in healthy adult subjects.
- Trial name
- NCT05845840
- Testing
- BRII-297
- Where
- Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Brii Biosciences Limited
Anhedonia, Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
- Trial name
- TERPSIS (NCT05165394)
- Testing
- NBI-1065846
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- Neurocrine Biosciences
Airway Obstruction, Sedation Complication
Evaluation of Medical Device for Airway Patency During Sedation (SW01-2022)
The goal of this four-part preclinical [I-II] and clinical [III-IV] trial is to compare, with randomised crossover study design [I-IV], a new medical airway device with standard procedure (biteblock or no device) for upper airway…
- Conditions
- Airway Obstruction, Sedation Complication, Safety Issues, Patient Satisfaction
- Trial name
- NCT05708651
- Testing
- Investigational device [I-IV], Comparator [I-IV]
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Stairway Medical AB
Depressive Episode, Depression
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
The objective of this study is to collect data to finalize the development of MEB-001 software as a medical device. The data collected in this study will be used to develop MEB-001 machine learning algorithms by training the…
- Conditions
- Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- SAMDE (NCT05708222)
- Testing
- MEB-001
- Where
- 13 sites in United States
- Volunteers
- 715 people
- Sponsor
- Medibio Limited
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Psoriasis
Post-Marketing Surveillance Study of OTEZLA
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1.
- Trial name
- NCT03284879
- Where
- Japan
- Volunteers
- 1,086 people
- Sponsor
- Amgen
Early Onset Alzheimer Disease, Mild Cognitive Impairment
Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain
Establishment of a BNA reference database for the Adult and Elderly Population. Hypothesis-generating study designed to collect data that will aid in future scientific and engineering exploration of correlations between clinical…
- Conditions
- Early Onset Alzheimer Disease, Mild Cognitive Impairment, Depression, Aging
- Trial name
- (BNA™) (NCT02875496)
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- ElMindA Ltd
Bipolar, Bipolar Disorder (BD)
Transcranial Photobiomodulation for Bipolar Depression
This study the effectiveness and safety of light therapy device targeted at the brain using a wearable device, the Vielight RX Gamma as a treatment for bipolar depression.
- Conditions
- Bipolar, Bipolar Disorder (BD), Bipolar Disorder Depression
- Trial name
- NCT07510646
- Testing
- Vielight Neuro Rx Gamma
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Vielight Inc.
Depression
Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)
This study is designed to characterize the regional distribution of [11C] ABP688 in brain by positron emission tomography (PET).
- Trial name
- NCT01528241
- Testing
- ABP688
- Where
- 2 sites in United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression, Suicide
Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults
The primary objective of the study is to estimate the incidence of suicide attempts resulting in a medical encounter or hospitalization in seven propensity matched cohorts of subjects: patients treated with duloxetine for…
- Trial name
- NCT00763724
- Volunteers
- 254,432 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder, Major Depressive Episode
Mobile Observation Of Depression
The primary aim of this project is to test if OCOsense glasses can function as a digital phenotyping tool derived from behavioural and physiological signals related to facial expression and motion recorded using the glasses.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Bipolar Disorder
- Trial name
- MOOD (NCT05815459)
- Testing
- OCOsense
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- Emteq Ltd